SCHEMBL3067178

SCHEMBL3067178

O=C(O)c1cnn(-c2ccccc2)c1N1CCCC(O)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
KEAP1 Q14145 1/20 0.52
NFE2L2 Q16236 1/20 0.52
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
NR4A3 Q92570 1/20 0.44
USP30 Q70CQ3 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TP53 P04637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
SLC9A1 P19634 1/20 0.40
SLC9A2 Q9UBY0 1/20 0.40
MAPK1 P28482 1/20 0.40
RIPK2 O43353 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075062 0.93 L3MBTL1 (0.56) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL3070448 0.87 MAPT (0.54) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL27783371 0.85 L3MBTL1 (0.50) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL3057279 0.85 L3MBTL1 (0.58) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL3068285 0.84 L3MBTL1 (0.64) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL3063443 0.83 L3MBTL1 (0.62) L3MBTL1KEAP1NFE2L2MEN1KMT2A
SCHEMBL3063351 0.82 HSD11B1 (0.52)
SCHEMBL3691093 0.81 CASR (0.48) MAPTALDH1A1KDM4E
SCHEMBL13962453 0.79 HSD11B1 (0.37) KEAP1NFE2L2MEN1KMT2ASMN1; SMN2
SCHEMBL3081434 0.77 L3MBTL1 (0.54) L3MBTL1KEAP1NFE2L2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101743226-B Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2012-10-10 CN claimed
CN-101743226-A Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2010-06-16 CN claimed
EP-2178845-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. Hoffmann-Roche AG (CH) 2010-04-28 EP claimed
WO-2009010416-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO claimed
CN-101743226-B Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2012-10-10 CN disclosed
US-7790711-B2 Inhibitors of 11β-Hydroxysteroid Dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-09-07 US disclosed
CN-101743226-A Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2010-06-16 CN disclosed
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase GILLESPIE PAUL 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase HSD17B1, HSD17B2, HSD11B1 L3MBTL1 3753/4885KEAP1 1004/4885NFE2L2 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.